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A B S T R A C T
Flow-cytometric detection of now termed measurable residual disease (MRD) in acute myeloid leukemia (AML)
has proven to have an independent prognostic impact. In a previous multicenter study we developed protocols to
accurately deﬁne leukemia-associated immunophenotypes (LAIPs) at diagnosis. It has, however, not been de-
monstrated whether the use of the deﬁned LAIPs in the same multicenter setting results in a high concordance
between centers in MRD assessment. In the present paper we evaluated whether interpretation of list-mode data
(LMD) ﬁles, obtained from MRD assessment of previously determined LAIPs during and after treatment, could
reliably be performed in a multicenter setting. The percentage of MRD positive cells was simultaneously de-
termined in totally 173 LMD ﬁles from 77 AML patients by six participating centers. The quantitative con-
cordance between the six participating centers was meanly 84%, with slight variation of 75%–89%. In addition
our data showed that the type and number of LAIPs were of inﬂuence on the performance outcome. The highest
concordance was observed for LAIPs with cross-lineage expression, followed by LAIPs with an asynchronous
antigen expression. Our results imply that immunophenotypic MRD assessment in AML will only be feasible
when fully standardized methods are used for reliable multicenter assessment.
1. Introduction
Acute myeloid leukemia (AML) is a heterogeneous malignant dis-
ease characterized by the accumulation of immature myeloid pro-
genitor cells, which leads to anemia, thrombocytopenia and impaired
immunity. Treatment with intensive chemotherapy regimens of adult
AML patients who are 60 years of age or younger results in hematologic
remission in about 70–90% of patients, but at least 30% of these pa-
tients will experience a relapse [1]. Remaining cells in the bone marrow
after chemotherapy treatment are thought to be responsible for the
relapse. The small number of malignant cells was previously termed
minimal residual disease, and is presently referred to as “measurable
residual disease” (MRD) [2]. Early relapse prediction is therefore of
high importance, so that post-remission therapy can be applied on time
and to decide on transplant or not. Treatment response assessment by
the quantiﬁcation of MRD is based on speciﬁc morphologic [3], im-
munophenotypic [4] or genotypic [5,6] aberrancies, and is one of the
predictors of relapse in AML. Often the residual leukemic cells are
present at levels below the sensitivity of conventional microscopic ex-
amination and the detection therefore requires more sensitive methods.
Real time quantitative PCR is the most sensitive method for the de-
tection of MRD in AML, but molecular markers suitable for follow-up
are available in about 60% of AML patients only [7]. Im-
munophenotypic detection of MRD by multiparameter ﬂow cytometry
(MFC) provides an useful alternative in the detection of MRD because it
allows: simultaneous identiﬁcation and quantiﬁcation of tumors cells at
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the single-cell-level, while fast and relatively cheap evaluation of high
cell numbers makes it possible to reliably deﬁne aberrant cell surface
antigen expression on AML blasts. These aberrant antigen combinations
of the leukemic cells, known as Leukemia-Associated Im-
munophenotypes (LAIPs), can be identiﬁed in nearly all patients with
AML at time of diagnosis [8] and are not, or at very low frequencies,
detectable on normal blasts. Immunophenotypic detection of MRD in
AML assessed after diﬀerent therapies has proven to deliver in-
dependent prognostic impact, mainly in single-institute studies [9–14],
but recently also in prospective multicentre studies [15,16]. Moreover,
measuring the extent of leukemic clearance by MRD assays determines
the resistance to therapy and thereby, importantly, can assess the re-
lapse risk in an individual patient independently from other risk factors.
As a result, the early detection of a forthcoming relapse might result in
risk adapted therapies.
For a previous multicenter study a working group was founded of
Dutch and Belgian laboratories with ample experience in ﬂow cyto-
metry that developed common protocols to accurately deﬁne LAIPs at
diagnosis required to establish MRD during/after treatment. In that
study we have shown that immunophenotypic MRD assessment is a
complex process that requires speciﬁc experience and standardization
in identiﬁcation of LAIPs between the laboratories involved [17]. It has,
however, not been demonstrated whether the use of the deﬁned LAIPs
in the same multicenter setting results in a high agreement between
centers in MRD assessment in follow up samples of AML treated pa-
tients.
The aim of the present study was to determine whether inter-
pretation of list-mode data (LMD) ﬁles obtained from im-
munophenotypic MRD assessment and based on LAIPs at diagnosis, can
reliably be evaluated for MRD detection, so that multiple laboratories
could concertedly provide MRD information of similar quality in mul-
ticenter trials.
2. Materials and methods
2.1. Patients and samples
Seventy seven 77 patients suﬀering from AML, consecutively pre-
senting and treated according to HOVON clinical trial 42a (www.
hovon.nl) in a period of about 3 years in the participating institutes,
were included. All patients had a cytopathologically conﬁrmed diag-
nosis according to the WHO classiﬁcation (excluding acute promyelo-
cytic leukemia). Bone marrow of patients treated for AML was obtained
at diagnosis and during follow-up after ﬁrst and second cycles of che-
motherapy according to the institutional protocols with given general
informed consent with central approval number Erasmus MC, METC
2000-220.
2.2. Participating laboratories/working group
All six participating institutes (arbitrary referred to as center 1–6)
are part of the AML-MRD ﬂow cytometry working group of the Dutch
Cytometry Society that was installed in 2004 with the main objective to
deﬁne the prerequisites for reliable multicenter MRD assessment in
studies with patients treated for AML. At that time all the laboratories
had longstanding experience in immunophenotyping of leukemia using
at least 4-color ﬂow cytometry and had experience in MRD assessment.
2.3. Data exchange and data reporting
All LMD ﬁles of the LAIPs run by the participating institutes on the
BM samples at diagnosis were already available in the coordinating
center (VUMC, Amsterdam) [17]. These LAIPs were also actually de-
signed and used by the institutes for MRD assessment of their own AML
patients and uploaded to the coordinating center for central MRD
analysis.
At twelve diﬀerent occasions during the three year study period, the
coordinating center selected LMD ﬁles of 5–7 cases for evaluation of
multicentric MRD assessment. Each case consisted of LMD ﬁles of the
selected LAIPs at diagnosis and the acquired data at follow-up. The
procedure of data exchange to the individual centers has been pre-
viously described [17]. Each institute analyzed the provided LMD ﬁles
for MRD assessment of the acquired follow-up samples of that particular
patient, using the same gating strategy according previously established
guidelines within the working group [11,16,17]. In short, analysis of
LAIP-positive cells included multiple backgating steps to ensure that,
compared with diagnosis, the LAIP-positive cells show fairly identical
positions in forward scatter channel/side scatter channel and CD45
expression. Each center reported independently (I) the number of LAIP
positive cells as percentage within the WBC compartment (%LAIP), and
(II) the interpretation of these analyzed LAIP data, by notifying whether
MRD is detectable and, if present, the percentage of MRD. Based on our
experience and outcome in previous studies [11,16], the working group
had agreed that the cut-oﬀ for MRD positivity in the present study
should also be set at 0.1%. Therefore all data reported between 0.05
and 0.1% were classiﬁed as MRD negative in the present analysis,
whereas all LAIP percentages reported below 0.05% were considered as
background values and therefore converted in the calculations to ne-
gative or zero. Concordance was determined by a qualitative and a
quantitative analysis. In case of qualitative analyses, the reported %
LAIP and MRD by the individual centers was classiﬁed as positive when
the percentage was 0.1 or higher and negative when the percentage was
below 0.1. The majority votes (MRD positive or MRD negative) per
sample were used, as denominators for comparisons. In those cases in
which votes on both sides were equal, the vote of the coordinator was
used to ﬁnally deﬁne the expected result. Concordance regarding
quantitative analyses of percentage LAIP and MRD was assessed by
deﬁning the median value of all the individual reported percentages of
each case as expected value.
In quarterly meetings of the working group the LAIP and MRD
percentages were discussed, and the performance of the participating
institutes were evaluated. While the coordinating center had access to
all ﬁles, the following precautions were taken to circumvent bias: MRD
assessment results from the patients uploaded to the coordinating
center by the ﬁve other centers, were downloaded by the coordinating
center only after having produced their own MRD analysis of each
uploaded sample. To avoid bias in cases where this was not possible, the
technician who performed the actual MRD analysis in the coordinating
center was diﬀerent from the one who gathered the X-drive data from
the other ﬁve centers.
2.4. Analyses of MRD
LMD ﬁles were exchanged with delivery of the identity of the LAIPs
as established at diagnosis, as well as the corresponding original diag-
nostic LMD ﬁles. MRD analysis was performed as previously described
[11]. Gating strategy of MRD in BM after the 1st or 2nd cycle of che-
motherapy is based on the LAIP expression in diagnosis AML material.
Analysis of LAIP-positive cells included multiple backgating steps to
ensure that, compared with the immunophenotyping at diagnosis, the
LAIP-positive cells show fairly identical positions in forward scatter
channel/side scatter channel and CD45 expression. By using this
method, LAIP-positive cell populations could be distinguished from
background expression in the gate. MRD percentage was deﬁned as the
percentage of LAIP-positive cells within the WBC compartment.
2.5. Statistics
Concordance of independent MRD data was assessed with the
Fischer’s exact test.
The intra-class correlation coeﬃcient (ICC) was used to estimate
correlations of MRD values between individual measurements and
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between average measurements made on the same target. The ICC was
calculated according to Shrout and Fleiss (Model 2, i.e., ICC2.1) [18].
The cut-oﬀ point of 0.75 ICC discriminates between good and moderate
to poor agreement of observed versus expected results.
3. Results
3.1. Analysis of LAIP-positive cells
In the present study six participating centers indepentdently ana-
lysed a total of 173 MRD LMD ﬁles from 77 patients (median: 2.2 per
patient, range: 1–4) according to analysis strategy of the working group
and reported the percentage LAIP positive cells of the total leucocytes
to the coordinating center. Regarding the qualitative concordance, the
expected nominated positives and negatives were compared with the
observed classiﬁed positives and negatives (see Methods). Using the
cut-oﬀ of > 0.1% for a positive sample, analysis of the LMD ﬁles re-
sulted in 73 expected positives (42%) and 100 expected negatives
(58%). The qualitative concordance of center 1–6 varied between 76%
and 91% with a mean of 86% (Table 1, last columns). Centers 4 and 6
had the highest agreement with the consensus, whereas center 3
showed the lowest concordance (Table 1). Sensitivity for individual
centers varied between 81% and 92%, whereas between centers there
was considerable more variation in the speciﬁcity between centers
ranging from 71 to 98% with an average of 86% (Table 1). Amongst all
388 positive data points, there were 56 false-negative assessments
(14%). Among all the 520 single negatives, there were 74 false-positive
assessments (14%). Fig. 1 shows the quantitative concordance of all
LAIP results as observed by all six centers versus the expected values.
Per center there are some diﬀerences in the agreement of their observed
values with respect to the expected values, as shown by the discordant
results, which were negative either by observation or by expectation
that are depicted on the axes together with the indicated numbers
(Fig. 1).
3.2. Impact of type of LAIP on qualitative concordance between centers
The kind of aberrancy present in the provided consensus LAIPs
identiﬁed at diagnosis [17] is related to the outcome of concordance
between centers (Table 2). Cross-lineage expression of LAIPs resulted in
the highest qualitative concordance for almost all centers with a mean
of 89%, followed by LAIPs with an asynchronous antigen expression
(mean 85%, last columns Table 2). LAIPs of more mature myeloid cells,
lacking CD34 and CD117, resulted in the lowest concordance (mean
79%). Especially, the latter had the highest percentage of false-nega-
tives from all 75 positive estimates: 13% compared to 6% and 5% for
asynchronous LAIPs and cross-lineage LAIPs, respectively. This results
in the lowest sensitivity (72%) compared to asynchronous (85%) and
cross-lineage (90%) LAIPS, respectively.
3.3. Analysis of MRD - qualitative
The next step was the interpretation of LAIP+ cells to determine
whether they do represent true MRD. The exchanged LMD were clas-
siﬁed as MRD-positive (31/77; 40%) and MRD-negative (46/77; 60%).
The qualitative concordance of center 1–6 varied between 77% and
96% with a mean of 85%. Centers 1 and 2 showed the highest agree-
ment with the consensus, whereas center 4 showed the lowest con-
cordance (Table 3). Between centers there was a substantial variation in
sensitivity, ranging from 61% to 100% (mean 82%), but less variation
in the speciﬁcity, ranging from 78 to 93% (mean 87%). From all 179
positive samples, there were 32 false-negative estimates (18%). Among
all the 240 single negative samples, there were 31 false-positive esti-
mates (13%) (Table 3).
Total agreement by all centers on the MRD-status was seen in 52%
of samples overall (MRD-pos 45%; MRD-neg 55%). Agreement by at
least 75% of centers that contributed (3 of 4, 4 of 5, or 5 of 6, since in
part of the cases only 4 or 5 of the 6 centers reported data) was found in
75% of the total submitted cases. In only 8 patients there was dis-
agreement between two centers and the other three or four centers.
Eleven patients remained with an equal vote for either results (3 MRD
positive, 3 MRD negative) on either side.
3.4. Analysis of MRD - quantitative
To determine concordance for the quantitative analyses of percen-
tage MRD, we calculated the median value of all the individual reported
percentages of each case and used this as the expected value, and
subsequently compared this with the observed value reported by each
center. Fig. 2 presents the diﬀerences of the six centers regarding the
agreement in their observed versus expected values. ICC analysis re-
sulted in an estimated correlation between individual centers of 0.62,
indicating moderate similarity between observations within a AML case
[18]. The estimated ICC between centers averaged over the six centers
is high, 0.91. As shown in Fig. 2 there is reasonable variation between
centers at low levels of MRD around the 0.1% cut-oﬀ, that is in samples
with values ranging between 0.05 and 0.2%, and as a consequence
resulting in false-positivity or false-negativity. From all 417 assess-
ments, there were in total 66 (16%) discordant (MRD-positive vs. MRD-
negative) between expected and observed quantitative MRD assess-
ments. Ten of these 66 discrepancies (15%) were due to only minor
diﬀerences of +/− 0.02% from expected quantitative values. Higher
Table 1
Qualitative a concordance in classiﬁcation of LAIP-positive cells by the diﬀerent centers.
Center 1 2 3 4 5 6 All Range
exp,obsb # % # % # % # % # % # % # % %
pos,pos 63 36 61 38 56 34 67 40 46 35 39 36 332 37
neg,neg 89 51 80 49 69 42 84 50 65 50 59 55 446 49
concordance 87 87 76 90 85 91 86 76–91
neg,posc 11 11 16 17 28 29 8 9 10 13 1 2 74 14
pos,negd 10 14 5 8 13 19 10 13 10 18 8 17 56 14
n = 173 162 166 169 131 107 908
sensitivitye 86 92 81 87 82 83 86 81–92
speciﬁcityf 89 83 71 91 87 98 86 71–98
a all percentages of LAIP equal or above cutoﬀ (> 0.1%) are classiﬁed as ‘positive’, below (< 0.1%) as ‘negative’.
b see method section for deﬁnition of expected versus observed result.
c false-positives= expected result is negative, whereas observation is positive.
d false-negatives= expected result is positive, whereas observation is negative.
e [(pos,pos)/[(pos,pos) + (pos,neg)]] * 100.
f [(neg,neg)/[(neg,pos) + (neg,neg)]] * 100.
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levels of MRD above 0.2% are closer in distance to the identity line. As
depicted in Fig. 2 almost all reported positive MRD percentages are
within one-log variance. MRD-positive values outside one-log varied
from 1 to a maximum of 3 outliers per center.
3.5. Impact of numbers of LAIPs on concordance in MRD percentage
Also the number of available LAIPs per AML follow up sample were
of inﬂuence on the concordance between centers. In 17 AML cases only
one LAIP and in 41 cases two LAIPs were identiﬁed at diagnosis,
whereas in 19 cases at least three LAIPs were selected. As shown in
Table 4 the overall agreement of 88% was the highest (center variation:
85%–93%) when two LAIPs were available for MRD interpretation. In
those cases with only one LAIP available for interpretation, the agree-
ment was only 77% (center variation: 72%–88%). The presence of at
least three LAIPs did not result in a better agreement compared to one
or two LAIPs.
Fig. 1. Percentage LAIP-positive cells as observed by center 1 to 6 versus the expected values. The expected values were derived from the median of all estimates per
sample. Each symbol represents one LAIP assessment. The diagonal lines in the quantitative part of the assay indicate the x= y, x= 3y and x=0.33y axes. All LAIP
percentages reported below 0.05% were considered as negative values and all concordantly negatives are cumulated on the intersection of x- and y-axis. Discordant
results, which were negative either by observation or by expectation, are depicted on the axes. Numbers in the graphs represent the number of samples per indicated
region.
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4. Discussion
The present study was undertaken to evaluate the performance of
laboratories in MRD assessment by MFC and especially to determine the
concordance between those centers that participate in a multicenter
setting. Moreover, the study was an attempt to establish critical issues
that require further improvement for reaching a high degree of con-
cordance in multicenter MRD assessment with MFC. Current MFC-based
methodologies for detection of MRD depend on establishing a LAIP at
diagnosis, and use this information at speciﬁed time points during or
after therapy for detection of MRD [8,16,19], or to apply a standardized
panel of antibody combinations for all MRD cases, irrespective the
availability of a diagnosis sample, in a diﬀerent-from-normal approach
[20,21]. Our method made use of the ﬁrst approach that provided a
description of immunophenotypic abnormalities (LAIPs) for a given
sample at diagnosis.
The observed qualitative concordance of the reported percentage of
LAIP positive cells by the 6 participating centers was on average 86%.
Performance of some centers were clearly better than others. Lowest
concordance by center 3 (76%) was mainly due to the relative high
number of observed false-positives resulting in a low speciﬁcity of 71%,
whereas center 6 with the highest concordance reached a speciﬁcity of
Table 2
Concordance a in percentage LAIP+ cells based on type of LAIPs.
Center 1 2 3 4 5 6 All Range
exp-obsb # % # % # % # % # % # % # %
Asynchronous antigen expression
pos,pos 20 31 22 39 18 30 19 31 15 33 11 35 105 33
neg,neg 37 58 27 48 24 40 37 61 21 46 18 58 164 52
concordance 89 87 70 92 89 93 85 70-93
neg,posc 3 7 6 18 13 35 0 0 8 28 0 0 30 15
pos,negd 4 17 1 4 5 22 5 21 2 12 2 15 19 15
n = 64 56 60 61 46 31 318
sensitivitye 83 96 78 79 88 85 85 78-96
speciﬁcityf 93 82 65 100 72 100 85 65-100
Crosslineage antigen expression
pos,pos 35 49 29 41 28 39 31 44 20 37 19 42 162 42
neg,neg 31 43 33 47 29 41 33 47 28 52 24 53 178 47
concordance 92 88 80 91 89 95 89 80-95
neg,posc 6 16 4 11 8 22 3 8 1 3 1 4 23 11
pos,negd 0 0 4 12 6 18 3 9 5 20 1 5 19 10
n = 72 70 71 70 54 45 382
sensitivitye 100 88 82 91 80 95 90 80-100
speciﬁcityf 84 89 78 92 97 96 89 78-97
Mature blasts
pos,pos 7 26 12 46 11 42 10 37 8 32 6 23 54 34
neg,neg 12 44 12 46 11 42 11 41 13 52 12 46 71 45
concordance 70 92 84 78 84 69 79 69-92
neg,posc 2 14 2 14 3 21 3 21 0 0 1 8 11 13
pos,negd 6 46 0 0 1 8 3 23 4 33 7 54 21 28
n = 27 26 26 27 25 26 157
sensitivitye 54 100 92 77 67 46 72 46-100
speciﬁcityf 86 86 79 79 100 92 87 79-100
a all percentages of LAIP equal or above cutoﬀ (> 0.1%) are classiﬁed as ‘positive’, below (< 0.1%) as ‘negative’.
b see method section for deﬁnition of expected versus observed result.
c false-positives= expected result is negative, whereas observation is positive.
d false-negatives= expected result is positive, whereas observation is negative.
e [(pos,pos)/[(pos,pos) + (pos,neg)]] * 100.
f [(neg,neg)/[(neg,pos) + (neg,neg)]] * 100.
Table 3
Qualitative a concordance in MRD assessment by the diﬀerent centers.
Center 1 2 3 4 5 6 All Range
exp,obsb # % # % # % # % # % # % # % %
pos,pos 33 43 28 37 27 37 20 26 20 33 19 35 147 35
neg,neg 41 53 40 53 31 42 39 51 31 52 27 50 209 50
concordance 96 90 79 77 85 85 85 77-96
neg,posc 3 7 4 9 9 22 5 11 5 14 4 13 31 13
pos,negd 0 0 4 12 6 18 13 39 4 17 4 17 32 18
n = 77 76 73 77 60 54 417
sensitivitye 100 88 82 61 83 83 82 61-100
speciﬁcityf 93 91 78 89 86 87 87 78-93
a all percentages of MRD equal or above cutoﬀ (> 0.1%) are classiﬁed as ‘positive’, below (< 0.1%) as ‘negative’.
b see method section for deﬁnition of expected versus observed result.
c false-positives= expected result is negative, whereas observation is positive.
d false-negatives= expected result is positive, whereas observation is negative.
e [(pos,pos)/[(pos,pos) + (pos,neg)]] * 100.
f [(neg,neg)/[(neg,pos) + (neg,neg)]] * 100.
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98%.
Also the type of LAIPs was of inﬂuence on the concordance between
centers in detection of the percentage LAIP positive cells in follow-up
samples. The highest concordance was observed for LAIP with cross-
lineage expression (89%), followed by LAIPs with an asynchronous
antigen expression. The lowest concordance (79%) was seen in those
cases where no primitive marker expression was found (mature LAIP),
resulting in a lower sensitivity as compared with the other type of
LAIPs. Especially, in the latter the sensitivity varied considerable be-
tween centers, i.e. 46% to 100%, indicating that centers had diﬃculty
with separating immunophenotypic aberrancy from regenerating BM,
due to less experience with these type of mature LAIPs in combination
with the fact that regenerating BM contains a higher percentage of
immature cells. In particular, center 1, 5 and 6 reported a relative high
Fig. 2. Correlation analysis of MRD results as observed by center 1 to 6 versus the expected values. The expected values were derived from the median of all estimates
per sample. Each symbol represents one MRD assessment. The diagonal lines in the quantitative part of the assay indicate the x= y, x=3y and x= 0.33y axes. All
MRD percentages reported below 0.05% were considered as negative values and all concordantly negatives are cumulated on the intersection of x- and y-axis.
Discordant results, which were negative either by observation or by expectation, are depicted on the axes. Numbers in the graphs represent the number of samples per
indicated region.
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number of false-negatives, resulting in a sensitivity of 54%, 67%, and
46%, respectively. Indeed, during the quarterly meetings of the working
group, where we evaluated the performance of the participating in-
stitutes, it became clear that the mature type of LAIP resulted in more
extensive discussions about MRD status than caused by the other type of
LAIP. Overall, the quality of the LAIP is important for the reliability of
the MRD assessment and depends not only on stability [22], but also on
speciﬁcity. Speciﬁcity is determined by the degree of aberrancy in
comparison with background expression in normal cells, and sensitivity
depends on the percentage of blasts presenting with that LAIP at di-
agnosis [11,23,24]. The background expression of a LAIP can be de-
termined on BM cells from healthy donors. However in clinical practice
the expression of presumed leukemia-speciﬁc immunophenotypes can
be very diﬀerent in BM samples that are regenerating after che-
motherapy [25]. In the multicenter approach of this study speciﬁcity
for a particular LAIP was deﬁned by each individual center, based on
experience. Thus to classify LAIP events as MRD may diﬀer between
centers and therefore requires further standardisation.
Next, based on the observed percentage of LAIP positive cells the
centers interpreted the available data whether or not these represent
true MRD. The qualitative concordance in absence or presence of MRD
of center 1–6 varied between 77% and 96% with a mean of 85%. The
lowest concordance of 77% by center 4 is related to the low observed
sensitivity by that center of 61%. This indicates that relatively high
number of false-negatives were reported in comparison with the other
centers. It shows that center 4 identiﬁed LAIP positive cells, but inter-
preted this as background in regenerating BM or not as a clear cluster of
cells.
As expected, similar results were found when we compared the
quantitative MRD concordance with the above qualitative MRD
concordance. The blinded inter-laboratory tests of LMD interpretation
showed overall a degree of quantitative concordance of 84% in MRD
assessment (mean qualitative concordance 85%) and varied among the
six centers between 75 and 89% (data not shown). The estimated ICC
between individual centers indicates a moderate similarity within an
AML case. A reason to ﬁnd moderate similarity is disagreement of one
or more of the six centers regarding an individual case. The causes of
discordance in MRD assessment between centers, as discussed at our
quarterly meetings, were mainly interpretation of background levels of
LAIP in regenerating bone marrow, quality of LAIPs, and shifts in gate
settings. Other causes in some cases were: MRD at limitation level of
detection (not enough events), phenotypic shifts, and in one particular
case in which autoﬂuorescence of the analysed cells after treatment had
eﬀect on the gate settings. A second reason for a lower ICC is related to
the variability in MRD values among subjects: the variability must be
large to demonstrate reliability. A lack of such variability can occur
when the MRD values are homogeneous (clustered to a small window of
analysis) or in situations that one or more observers are stricter than
others in their data analysis. In the present study the variability was not
that large, since almost half of the follow-up samples that were assessed
for MRD were reported as negative or zero (45% of total) and about a
quarter were reported between 0.05% and 0.2% (27% of total). In cases
with an observed percentage of LAIP positive cells around the cut-oﬀ of
0.1%, a lower agreement between centers is reached. In 15% of all
expected versus observed discrepancies for quantitative MRD assess-
ment were due to only minor variation of 0.02% in quantitation. This
pinpoints to a serious limitation of a pre-deﬁned cut-oﬀ: several studies
have revealed that often a single cut-oﬀ level that deﬁnes MRD-positive
and MRD-negative patient groups results on the one hand in a patient
sub-group who classiﬁed as MRD-positive, but remained in complete
Table 4
Concordancea in MRD assessment based on number of available LAIPs.
Center 1 2 3 4 5 6 All Range
exp-obsb # % # % # % # % # % # % # % %
One LAIP
pos,pos 7 41 5 31 6 43 6 35 4 27 4 29 32 34
neg,neg 7 41 7 44 4 29 9 53 7 47 6 43 40 43
concordance 82 75 72 88 74 72 77 72-88
neg,posc 2 22 2 22 3 43 0 0 2 22 2 25 11 22
pos,negd 1 12 2 29 1 14 2 25 2 33 2 33 10 24
n = 17 16 14 17 15 14 93
sensitivitye 88 71 86 75 67 67 76 67-88
speciﬁcityf 78 78 57 100 78 75 78 57-100
Two LAIPs
pos,pos 13 32 11 27 11 28 8 20 9 26 10 31 62 27
neg,neg 25 61 26 63 23 58 25 61 22 65 19 59 140 61
concordance 93 90 86 81 91 90 88 81-93
neg,posc 3 11 2 7 4 15 3 11 2 8 2 9 16 10
pos,negd 0 0 2 15 2 15 5 38 1 10 1 9 11 15
n = 41 41 40 41 34 32 229
sensitivitye 100 85 85 62 90 91 85 62-100
speciﬁcityf 89 93 85 89 92 91 90 85-93
Three LAIPs
pos,pos 9 47 9 47 7 37 6 32 6 55 4 50 41 43
neg,neg 7 37 8 42 5 26 8 42 4 36 4 50 36 38
concordance 74 89 63 74 91 100 81 63-100
neg,posc 2 22 1 11 4 44 1 11 1 20 0 0 9 20
pos,negd 1 10 1 10 3 30 4 40 0 0 0 0 9 18
n = 19 19 19 19 11 8 95
sensitivitye 90 90 70 60 100 100 82 60-100
speciﬁcityf 78 89 56 89 80 100 80 56-100
a all percentages of LAIP cells equal or above cutoﬀ (> 0.1%) are classiﬁed as ‘positive’, below (< 0.1%) as ‘negative’.
b see method section for deﬁnition of expected versus observed result.
c false-positives= expected result is negative, whereas observation is positive.
d false-negatives= expected result is positive, whereas observation is negative.
e [(pos,pos)/[(pos,pos) + (pos,neg)]] * 100.
f [(neg,neg)/[(neg,pos) + (neg,neg)]] * 100.
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remission. On the other hand, patient sub-groups who classiﬁed as MRD
negative, but nevertheless relapsed, may be consistent with residual
leukemia [15,16,26,27].
Our data also show that the number of available LAIPs per AML
follow up sample were of inﬂuence on the concordance between cen-
ters. In those cases that only one LAIP was available for interpretation
the agreement was only 77%. When however, two LAIPs were available
for MRD interpretation the overall agreement was much higher (88%).
The presence of at least three LAIPs resulted not in a better agreement
than in the presence of only one or two LAIPs. One of the explanations
could be that the third and more extra deﬁned LAIPs are not based on
additional aberrancies observed at diagnosis, but were in most cases
overlapping variants of the ﬁrst and second deﬁned LAIP, so the same
markers but with other ﬂuorochrome combinations. Secondly, when
more than two LAIPs are available it can occur that the percentages of
LAIP positive cells are more often discordant among these LAIPs, and
therefore making the interpretation more diﬃcult. However, it is also
important, whenever possible, to include more than one LAIP for MRD
detection to prevent that post-therapeutic changes in im-
munophenotype are missed, e.g. due to selection by therapy of minor
sub-populations. Such selections have been shown to occur for mole-
cular clones [28], which may hypothetically be reﬂected in mutational
and immunophenotypical changes [29,30].
To reach a high sensitivity it is essential to use highly informative
antibody combinations in the LAIP. A disadvantages in this study was
the use four-color antibody combinations that limits the possible anti-
body combinations and as a result limits the speciﬁcity and thereby the
sensitivity of AML-speciﬁc events. Nowadays 8–10 colors are routinely
used; this likely allows a more speciﬁc assessment of aberrancies.
Nevertheless, the present study shows that a high variability is for a
large part due to subjective interpretation, as is characteristic for the
limitations of current MFC MRD protocols for AML.
An important advantage of using ﬂow cytometric MRD assessment
over PCR-based MRD detection in AML patients lies in the fact that MFC
is applicable to virtually all patients [31–33], and is easily quantiﬁable
with the additional ability to distinguish live from dead cells. Above
that, it is considered as a less labor-intensive and faster MRD technique
as compared to PCR. Nevertheless, it is logical that approaches com-
bining molecular techniques and MFC also have been used, leading to
improvement of MRD stratiﬁcation in AML [34,35]. Next-generation
sequencing (NGS) can be another application in the near future, since
NGS enables the detection of molecular minimal residual disease in
virtually every AML patient. A recent study where sequencing was
compared with ﬂow cytometry for the detection of residual disease
showed that sequencing had signiﬁcant additive prognostic value [36].
In conclusion, our study has shown that the analysis of acquired
ﬂowcytometric data to determine the level of MRD is a complex process
that requires speciﬁc experience.
Nevertheless our results imply that immunophenotypic MRD as-
sessment in AML will only be feasible when standardized methods are
used for reliable multicentre assessment in large clinical trials. For that
reason we think that more objective methods to identify and quantify
aberrant cells will be necessary to ﬁnally allow implementation in
standard diagnostic care.
Further improvement for reaching a higher degree of concordance
in multicenter MRD assessment with MFC could be obtained by using:
1) multicolour immunostaining protocols using ≥ 8 colors that will
likely go along with an improved speciﬁcity of MRD assessment by
MFC; 2) standardization of every aspect of immunophenotypic MRD
monitoring, including uniformity in the applied immunostaining pro-
tocols, antibody panels, acquisition [37,38], 3) automated gating stra-
tegies that probably have the largest impact on standardization. Several
multidimensional analysis programs, originally developed for Cytof
applications, are being adapted for MFC [39], including MRD [40–42].
Since MRD evaluation is becoming the new standard in evaluating re-
sponse in AML [20,26,43], eﬀorts need to be made by all laboratories
involved in MRD detection to follow these uniﬁed standardized proto-
cols, so that the results are comparable and reduce the inter-laboratory
variability. In that respect, a consensus document that provides
guidelines for MRD detection and its clinical use, has recently been
published by the European Leukemia Net MRD working party [44].
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